Compare Stocks → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:FMTXNASDAQ:IMVTNASDAQ:KRYSNASDAQ:REPLNASDAQ:RGNX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFMTXForma Therapeutics$20.01$20.00$4.95▼$20.68$957.54M-0.94847,595 shs1 shsIMVTImmunovant$27.75-3.6%$32.30$15.90▼$45.58$4.03B0.651.22 million shs1.27 million shsKRYSKrystal Biotech$155.68-2.1%$163.46$82.09▼$189.97$4.44B0.85366,250 shs242,413 shsREPLReplimune Group$6.15-2.8%$7.86$5.86▼$24.81$377.54M1.211.33 million shs783,453 shsRGNXREGENXBIO$16.06+0.1%$19.97$11.83▼$28.80$787.58M1.29719,818 shs604,238 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFMTXForma Therapeutics0.00%0.00%0.00%0.00%0.00%IMVTImmunovant-3.65%-2.01%-11.71%-27.45%+72.47%KRYSKrystal Biotech-2.12%-5.06%-10.62%+34.17%+82.04%REPLReplimune Group-2.84%-11.76%-20.03%-20.95%-63.17%RGNXREGENXBIO+0.12%-0.31%-25.89%+26.26%-12.72%Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFMTXForma TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIMVTImmunovant3.0124 of 5 stars4.53.00.00.02.51.70.0KRYSKrystal Biotech4.0999 of 5 stars2.51.00.04.72.73.31.9REPLReplimune Group4.4921 of 5 stars3.51.00.04.53.73.31.3RGNXREGENXBIO4.5933 of 5 stars4.41.00.04.62.83.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFMTXForma TherapeuticsN/AN/AN/AN/AIMVTImmunovant3.00Buy$48.0072.97% UpsideKRYSKrystal Biotech3.00Buy$171.009.84% UpsideREPLReplimune Group3.00Buy$37.67512.47% UpsideRGNXREGENXBIO2.83Moderate Buy$38.45139.44% UpsideCurrent Analyst RatingsLatest KRYS, IMVT, RGNX, FMTX, and REPL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$200.004/16/2024KRYSKrystal BiotechStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$178.00 ➝ $204.004/12/2024RGNXREGENXBIOStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/28/2024IMVTImmunovantOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$50.003/25/2024IMVTImmunovantTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$48.003/13/2024IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.003/11/2024RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$36.003/8/2024RGNXREGENXBIORoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSector Perform ➝ Outperform$20.00 ➝ $35.003/7/2024RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.003/7/2024RGNXREGENXBIOBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$45.00 ➝ $55.003/6/2024RGNXREGENXBIOLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFMTXForma Therapeutics$100.56M9.52N/AN/A$10.51 per share1.90IMVTImmunovantN/AN/AN/AN/A$2.78 per shareN/AKRYSKrystal Biotech$50.70M87.54N/AN/A$27.60 per share5.64REPLReplimune GroupN/AN/AN/AN/A$9.80 per shareN/ARGNXREGENXBIO$90.24M8.73N/AN/A$7.09 per share2.27Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFMTXForma Therapeutics-$172.96M-$4.00N/AN/AN/AN/A-39.68%-35.33%N/AIMVTImmunovant-$210.96M-$1.84N/AN/AN/AN/A-57.97%-52.47%5/27/2024 (Estimated)KRYSKrystal Biotech$10.93M$0.081,946.2439.31N/AN/A-13.31%-12.61%5/13/2024 (Estimated)REPLReplimune Group-$174.28M-$3.16N/AN/AN/AN/A-42.94%-35.80%5/16/2024 (Estimated)RGNXREGENXBIO-$263.49M-$6.03N/AN/AN/A-291.99%-68.18%-39.95%5/1/2024 (Estimated)Latest KRYS, IMVT, RGNX, FMTX, and REPL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/27/2024Q4 2023RGNXREGENXBIO-$1.27-$1.43-$0.16-$1.43$34.01 million$22.30 million 2/26/202412/31/2023KRYSKrystal Biotech-$0.52$0.30+$0.82$0.30$27.43 million$42.14 million 2/12/202412/31/2023IMVTImmunovant-$0.43-$0.36+$0.07-$0.36N/AN/A2/8/2024Q3 2024REPLReplimune Group-$0.89-$0.77+$0.12-$0.77N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFMTXForma TherapeuticsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFMTXForma TherapeuticsN/A12.7412.74IMVTImmunovantN/A22.1422.14KRYSKrystal BiotechN/A17.7617.55REPLReplimune Group0.1612.4012.40RGNXREGENXBION/A2.572.57OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFMTXForma Therapeutics87.39%IMVTImmunovant47.08%KRYSKrystal Biotech86.29%REPLReplimune Group92.53%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipFMTXForma Therapeutics5.79%IMVTImmunovant4.80%KRYSKrystal Biotech14.10%REPLReplimune Group20.60%RGNXREGENXBIO13.13%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableFMTXForma Therapeutics16647.85 million45.08 millionNot OptionableIMVTImmunovant164145.29 million138.32 millionOptionableKRYSKrystal Biotech22928.51 million24.49 millionOptionableREPLReplimune Group28461.39 million48.74 millionOptionableRGNXREGENXBIO34449.04 million42.60 millionOptionableKRYS, IMVT, RGNX, FMTX, and REPL HeadlinesSourceHeadlineREGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summitprnewswire.com - April 24 at 7:05 AMREGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Raymond James & Associatesmarketbeat.com - April 23 at 4:04 AMMirae Asset Global Investments Co. Ltd. Reduces Holdings in REGENXBIO Inc. (NASDAQ:RGNX)marketbeat.com - April 21 at 4:35 AMKenneth T. Mills Sells 15,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX) Stockinsidertrades.com - April 19 at 5:32 AMREGENXBIO (NASDAQ:RGNX) Stock Price Down 3.1% Following Insider Sellingamericanbankingnews.com - April 19 at 1:22 AMREGENXBIO (NASDAQ:RGNX) Shares Down 3.1% Following Insider Sellingmarketbeat.com - April 18 at 11:42 AMInsider Selling: REGENXBIO Inc. (NASDAQ:RGNX) CEO Sells 15,000 Shares of Stockmarketbeat.com - April 17 at 6:39 PMREGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measuresfinance.yahoo.com - April 17 at 10:55 AMWhere Regenxbio Stands With Analystsmarkets.businessinsider.com - April 12 at 1:03 PMREGENXBIO (NASDAQ:RGNX) Earns "Buy" Rating from Stifel Nicolausmarketbeat.com - April 12 at 12:15 PMREGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Brokeragesmarketbeat.com - April 6 at 2:58 AMAssenagon Asset Management S.A. Invests $1.92 Million in REGENXBIO Inc. (NASDAQ:RGNX)marketbeat.com - April 5 at 4:29 AMRegenxbio Stock (NASDAQ:RGNX), Quotes and News Summarybenzinga.com - March 31 at 10:27 PMREGENXBIO (NASDAQ:RGNX) Stock Price Down 2%marketbeat.com - March 28 at 4:33 PMREGENXBIO Sees Positive Results For Macular Degeneration Therapyfinance.yahoo.com - March 28 at 1:40 PMREGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDprnewswire.com - March 28 at 7:05 AMREGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Daysfinance.yahoo.com - March 27 at 5:33 PMREGENXBIO Inc. (NASDAQ:RGNX) CEO Sells $327,900.00 in Stockinsidertrades.com - March 19 at 5:00 AMRegenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Sharesfinance.yahoo.com - March 18 at 9:18 PMREGENXBIO Inc. (NASDAQ:RGNX) Insider Steve Pakola Sells 12,878 Sharesinsidertrades.com - March 17 at 7:41 AMRockville biotech raises $140M following layoffs, program cutsbizjournals.com - March 12 at 8:13 PMRegenxbio: DMD Program Lends Additional Credibility To NAV Technology Platformseekingalpha.com - March 11 at 2:02 PMRegenxbio initiated with bullish view at H.C. Wainwright, here's whyrealmoney.thestreet.com - March 11 at 2:02 PMREGENXBIO to Participate in Upcoming Investor Conferencesprnewswire.com - March 11 at 7:05 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsForma TherapeuticsNASDAQ:FMTXForma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.ImmunovantNASDAQ:IMVTImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Krystal BiotechNASDAQ:KRYSKrystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Replimune GroupNASDAQ:REPLReplimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.REGENXBIONASDAQ:RGNXREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.